CO2019011578A2 - Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo - Google Patents
Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararloInfo
- Publication number
- CO2019011578A2 CO2019011578A2 CONC2019/0011578A CO2019011578A CO2019011578A2 CO 2019011578 A2 CO2019011578 A2 CO 2019011578A2 CO 2019011578 A CO2019011578 A CO 2019011578A CO 2019011578 A2 CO2019011578 A2 CO 2019011578A2
- Authority
- CO
- Colombia
- Prior art keywords
- crystalline form
- preparing
- salt
- aminopyridine
- compound derived
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
- C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170051687 | 2017-04-21 | ||
| PCT/KR2018/004473 WO2018194356A1 (en) | 2017-04-21 | 2018-04-18 | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019011578A2 true CO2019011578A2 (es) | 2020-02-28 |
Family
ID=63857137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0011578A CO2019011578A2 (es) | 2017-04-21 | 2019-10-18 | Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11453656B2 (enExample) |
| EP (1) | EP3612529A4 (enExample) |
| JP (2) | JP7126514B2 (enExample) |
| KR (3) | KR102629654B1 (enExample) |
| CN (1) | CN110869367B (enExample) |
| AR (1) | AR111469A1 (enExample) |
| AU (2) | AU2018256227B2 (enExample) |
| CA (1) | CA3059543A1 (enExample) |
| CO (1) | CO2019011578A2 (enExample) |
| EA (1) | EA201992501A1 (enExample) |
| IL (2) | IL294666B2 (enExample) |
| MA (1) | MA49696A (enExample) |
| MX (2) | MX392634B (enExample) |
| MY (1) | MY201919A (enExample) |
| NZ (1) | NZ758443A (enExample) |
| PH (1) | PH12019502370A1 (enExample) |
| SA (1) | SA519410342B1 (enExample) |
| SG (1) | SG11201909615YA (enExample) |
| TW (1) | TWI776882B (enExample) |
| UA (1) | UA124364C2 (enExample) |
| WO (1) | WO2018194356A1 (enExample) |
| ZA (1) | ZA201907687B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12187714B2 (en) | 2017-07-28 | 2025-01-07 | Yuhan Corporation | Process for preparing aminopyrimidine derivatives |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| KR20200043618A (ko) * | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| KR101973074B1 (ko) * | 2018-11-30 | 2019-04-26 | 주식회사 티움바이오 | 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물 |
| CN111349084B (zh) * | 2018-12-21 | 2022-11-25 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的氨基嘧啶类化合物 |
| MX2021010265A (es) | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| MY208668A (en) | 2019-05-14 | 2025-05-23 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors |
| BR112021022828A2 (pt) * | 2019-05-14 | 2022-04-12 | Janssen Biotech Inc | Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| BR112022015140A2 (pt) | 2020-02-12 | 2022-10-11 | Janssen Biotech Inc | Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met |
| TWI923583B (zh) * | 2020-04-14 | 2026-05-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物 |
| EP4349835A4 (en) * | 2021-06-01 | 2025-06-25 | Hangzhou Solipharma Co., Ltd. | Hydrated crystal form of lazertinib methanesulfonate, process for its preparation and use thereof |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| IL326946A (en) | 2023-09-05 | 2026-05-01 | Janssen Biotech Inc | Methods of treating non-small cell lung cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE025742T2 (hu) | 2003-12-25 | 2016-04-28 | Eisai R&D Man Co Ltd | 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra |
| PL1720853T3 (pl) | 2004-02-11 | 2016-06-30 | Natco Pharma Ltd | Nowa odmiana polimorficzna metanosulfonianu imatynibu i sposób jej otrzymywania |
| AU2009262068C1 (en) | 2008-06-27 | 2015-07-02 | Celgene Car Llc | Heteroaryl compounds and uses thereof |
| CZ2009570A3 (cs) | 2009-08-26 | 2011-03-09 | Zentiva, K. S. | Príprava, stabilizace a využití polymorfu imatinib mesylátu pro vývoj lékových forem |
| CA2780892C (en) * | 2009-11-13 | 2017-02-14 | Genosco | Kinase inhibitors |
| WO2012077136A2 (en) * | 2010-12-06 | 2012-06-14 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
| DK3686193T3 (da) * | 2011-07-27 | 2022-05-30 | Astrazeneca Ab | 2-(2,4,5-substitueret anilino)pyrimidinforbindelser |
| CN104540822B (zh) | 2013-07-08 | 2016-08-31 | 杭州普晒医药科技有限公司 | 达拉菲尼甲磺酸盐的晶型及其制备方法 |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| EP3929190B1 (en) * | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| CN104788427B (zh) | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| KR101794186B1 (ko) | 2015-10-30 | 2017-11-08 | 한국기술교육대학교 산학협력단 | 전기자동차용 급전장치 |
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
-
2018
- 2018-04-13 AR ARP180100945A patent/AR111469A1/es not_active Application Discontinuation
- 2018-04-18 AU AU2018256227A patent/AU2018256227B2/en active Active
- 2018-04-18 CA CA3059543A patent/CA3059543A1/en active Pending
- 2018-04-18 EP EP18787260.1A patent/EP3612529A4/en active Pending
- 2018-04-18 TW TW107113234A patent/TWI776882B/zh active
- 2018-04-18 MX MX2019012574A patent/MX392634B/es unknown
- 2018-04-18 NZ NZ758443A patent/NZ758443A/en unknown
- 2018-04-18 CN CN201880026342.7A patent/CN110869367B/zh active Active
- 2018-04-18 UA UAA201911263A patent/UA124364C2/uk unknown
- 2018-04-18 MY MYPI2019006145A patent/MY201919A/en unknown
- 2018-04-18 MA MA049696A patent/MA49696A/fr unknown
- 2018-04-18 US US16/605,944 patent/US11453656B2/en active Active
- 2018-04-18 SG SG11201909615Y patent/SG11201909615YA/en unknown
- 2018-04-18 EA EA201992501A patent/EA201992501A1/ru unknown
- 2018-04-18 JP JP2019556610A patent/JP7126514B2/ja active Active
- 2018-04-18 IL IL294666A patent/IL294666B2/en unknown
- 2018-04-18 IL IL270018A patent/IL270018B/en unknown
- 2018-04-18 KR KR1020180044850A patent/KR102629654B1/ko active Active
- 2018-04-18 WO PCT/KR2018/004473 patent/WO2018194356A1/en not_active Ceased
-
2019
- 2019-10-18 CO CONC2019/0011578A patent/CO2019011578A2/es unknown
- 2019-10-18 PH PH12019502370A patent/PH12019502370A1/en unknown
- 2019-10-20 SA SA519410342A patent/SA519410342B1/ar unknown
- 2019-10-21 MX MX2022006357A patent/MX2022006357A/es unknown
- 2019-11-20 ZA ZA2019/07687A patent/ZA201907687B/en unknown
-
2022
- 2022-03-17 US US17/697,655 patent/US11981659B2/en active Active
- 2022-05-23 AU AU2022203486A patent/AU2022203486B2/en active Active
- 2022-08-16 JP JP2022129468A patent/JP7390444B2/ja active Active
-
2023
- 2023-12-18 KR KR1020230184208A patent/KR102835717B1/ko active Active
-
2024
- 2024-03-27 US US18/618,379 patent/US12428401B2/en active Active
-
2025
- 2025-07-11 KR KR1020250093917A patent/KR20250111074A/ko active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12187714B2 (en) | 2017-07-28 | 2025-01-07 | Yuhan Corporation | Process for preparing aminopyrimidine derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006357A (es) | Sal de un compuesto derivado de aminopiridina, una forma cristalina de esta, y un proceso para prepararlo. | |
| EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
| EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
| EA202091115A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| MX389672B (es) | Inhibidores de ssao de aminopirimidina | |
| MX391812B (es) | Agonista fxr derivado de esteroides. | |
| EA201591531A1 (ru) | Ингибиторы аргининметилтрансферазы и их применения | |
| CY1122182T1 (el) | Ανοσοκατασταλτικες φαρμακοτεχνικες μορφες | |
| BR112016015365A8 (pt) | composto, composição farmacêutica e uso de um composto | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| MX380546B (es) | Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos. | |
| EA201591649A1 (ru) | Составы с органическими соединениями | |
| ECSP21067104A (es) | Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas | |
| EA201690390A1 (ru) | Производные амидов в качестве антагонистов рецептора к лизофосфатидной кислоте | |
| EA201592268A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 | |
| EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
| EA201891682A1 (ru) | Производное азациклического амида, способ его получения и фармацевтическое применение | |
| EA201591795A1 (ru) | Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120 | |
| CY1125052T1 (el) | Κρυσταλλικες μορφες | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| EA201691741A1 (ru) | Фармацевтическая композиция | |
| EA201500941A1 (ru) | Способы и композиции для модуляции гамма-глутамилового цикла |